XRAYS - Making Sense of Cancer Headlines

FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.

XRAYS logo and women

Read the topic that we reviewed this week

STUDY: Can some women with early-stage breast cancer forego chemotherapy?

XRAYS Rating
XRAYS study

A research study named the “Trial Assigning Individualized Options for Treatment” (TAILORx) asked whether chemotherapy is beneficial for women who have mid-range Oncotype DX tumor recurrence scores. This trial — the largest breast cancer treatment trial ever conducted— showed that endocrine therapy alone was as effective as endocrine therapy plus chemotherapy in women with certain types of early-stage breast cancer. The results of this trial are expected to be immediately practice changing (7/20/18)

Search for reviews by category, keyword or date or browse our recent articles below

Featured Studies and Articles

XRAYS Rating

ARTICLE: High health insurance deductibles can interfere with breast cancer treatment decisions

A New York Times article published on May 4, 2018 examines the impact of high insurance deductibles on breast cancer treatment. (7/12/18)

XRAYS Rating

STUDY: Evaluation of some direct-to-consumer genetic testing reveals inaccuracies and misinterpretations

A clinical genetic testing laboratory examined results from direct-to-consumer genetic testing ordered directly by patients. They found many instances of false positives—reported mutations that were not actually present—and in some cases, reports of variants that "increased risk," but were actually benign. This study emphasized the importance of involving genetics experts in the interpretation of genetic test results. (6/28/18)

XRAYS Rating

STUDY: Disparities in research impact breast screening guidelines

For women at average risk of breast cancer, the United States Preventive Services Task Force (USPSTF) currently recommends beginning annual breast cancer screening at age 50. However, because these guidelines are largely based on data from white women, they may not be sensitive to racial differences.  A new study assesses the age distribution of breast cancer cases across race/ethnicity in the U.S. (6/21/18)

XRAYS Rating

STUDY: Mutations in Lynch syndrome genes MSH6 and PMS2 are associated with breast cancer

A research study published in Genetics in Medicine earlier this year shows that women with mutations in MSH6 and PMS2, two Lynch syndrome genes, have a modest (2 to 3-fold) but significantly increased risk for breast cancer. Lynch syndrome mutations have a known risk of colorectal, ovarian and uterine/endometrial cancer, as well as many other cancers. This is the first study to evaluate breast cancer risk in women with mutations in specific Lynch syndrome genes. (6/14/18)

Find older XRAYS studies and articles

By keyword search:

By date range:

FORCE:Facing Our Risk of Cancer Empowered